Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer

MLA

Bo Nordenskjöld, et al. “Assessment of Long-Term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.” JAMA Oncology, vol. 5, Sept. 2019, p. 1304. EBSCOhost, https://doi.org/10.1001/jamaoncol.2019.1856.

APA

Bo Nordenskjöld, Kamila Czene, Christina Yau, Christopher C. Benz, Nancy Yiu-Lin Yu, Linda S. Lindström, Nicholas P. Tobin, Laura J. Esserman, Tommy Fornander, Katherine A. Hoadley, Adina Iftimi, Laura van ’t Veer, & Olle Stål. (2019). Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. JAMA Oncology, 5, 1304. https://doi.org/10.1001/jamaoncol.2019.1856

Chicago

Bo Nordenskjöld, Kamila Czene, Christina Yau, Christopher C. Benz, Nancy Yiu-Lin Yu, Linda S. Lindström, Nicholas P. Tobin, et al. 2019. “Assessment of Long-Term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.” JAMA Oncology 5 (September): 1304. doi:10.1001/jamaoncol.2019.1856.